IL137761A0 - Treatment of multiple sclerosis using cop-1 and th-2 enhancing cytokines - Google Patents

Treatment of multiple sclerosis using cop-1 and th-2 enhancing cytokines

Info

Publication number
IL137761A0
IL137761A0 IL13776199A IL13776199A IL137761A0 IL 137761 A0 IL137761 A0 IL 137761A0 IL 13776199 A IL13776199 A IL 13776199A IL 13776199 A IL13776199 A IL 13776199A IL 137761 A0 IL137761 A0 IL 137761A0
Authority
IL
Israel
Prior art keywords
cop
treatment
multiple sclerosis
enhancing cytokines
cytokines
Prior art date
Application number
IL13776199A
Other languages
English (en)
Original Assignee
Autoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autoimmune Inc filed Critical Autoimmune Inc
Publication of IL137761A0 publication Critical patent/IL137761A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL13776199A 1998-02-13 1999-02-12 Treatment of multiple sclerosis using cop-1 and th-2 enhancing cytokines IL137761A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7469698P 1998-02-13 1998-02-13
PCT/US1999/003308 WO1999041247A1 (fr) 1998-02-13 1999-02-12 Traitement de la sclerose en plaques en utilisant le cop-1 et les cytokines de renforcement des th2

Publications (1)

Publication Number Publication Date
IL137761A0 true IL137761A0 (en) 2001-10-31

Family

ID=22121111

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13776199A IL137761A0 (en) 1998-02-13 1999-02-12 Treatment of multiple sclerosis using cop-1 and th-2 enhancing cytokines

Country Status (9)

Country Link
US (1) US20010007758A1 (fr)
EP (1) EP1054880A1 (fr)
JP (1) JP2002503658A (fr)
KR (1) KR20010052170A (fr)
AU (1) AU2868699A (fr)
CA (1) CA2320044A1 (fr)
HU (1) HUP0100891A2 (fr)
IL (1) IL137761A0 (fr)
WO (1) WO1999041247A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4328050B2 (ja) * 2000-01-20 2009-09-09 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 神経保護療法のためのコポリマー１、関連ペプチド及びポリペプチドならびにそれらによって処理されたｔ細胞の使用
EP1294390B1 (fr) * 2000-06-07 2006-01-04 YEDA RESEARCH AND DEVELOPMENT CO., Ltd. Utilisation du copolymere 1 et des peptides et polypeptides associes, et lymphocytes t traites par ces derniers pour une therapie neuroprotectrice contre la toxicite de la glutamate
US7790158B2 (en) * 2001-09-25 2010-09-07 The Regents Of The University Of California Methods for epitope-specific and cytokine/anticytokine combination immunotherapies
US7351686B2 (en) * 2001-12-06 2008-04-01 Yeda Research And Development Co. Ltd. Method for neuronal protection in amyotrophic lateral sclerosis by a vaccine comprising Copolymer-1 or Copolymer-1 related peptides
ES2386435T3 (es) * 2003-01-07 2012-08-21 Yeda Research And Development Co., Ltd. Vacuna en forma de gotas oculares que contiene copolímero 1 para inmunización terapéutica
CA2556152A1 (fr) * 2004-02-02 2005-08-18 Mixture Sciences, Inc. Melanges de peptides a activite immunomodulatrice
US7655221B2 (en) * 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
US20050281885A1 (en) * 2004-06-21 2005-12-22 Egilmez Nejat K Method for treating inflammatory bowel disease by oral administration of IL-10
ES2541780T3 (es) * 2004-11-29 2015-07-24 Yeda Research And Development Co., Ltd. Inducción de la neurogénesis y terapia con células madre en combinación con el Copolímero 1
ES2329327B1 (es) 2008-03-19 2010-09-17 Proyecto De Biomedicina Cima, S.L. Combinaciones sinergicas de 5'-metiltioadenosina.
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN109982712A (zh) 2016-08-31 2019-07-05 Mapi医药公司 包含醋酸格拉替雷的储库系统
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
KR20210092535A (ko) 2020-01-16 2021-07-26 김삼중 이동식 무선 신분증 위변조 검사 시스템 및 그 운용방법
JP7782598B2 (ja) * 2024-02-27 2025-12-09 栗田工業株式会社 ２段電気脱イオンシステムの運転方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US5627206A (en) * 1995-06-02 1997-05-06 Warner-Lambert Company Tricyclic inhibitor of matrix metalloproteinases
US5817757A (en) * 1995-10-30 1998-10-06 Merck & Co., Inc. Inhibitors of peptide binding to MHO class II proteins

Also Published As

Publication number Publication date
AU2868699A (en) 1999-08-30
CA2320044A1 (fr) 1999-08-19
EP1054880A1 (fr) 2000-11-29
KR20010052170A (ko) 2001-06-25
WO1999041247A1 (fr) 1999-08-19
HUP0100891A2 (hu) 2001-06-28
JP2002503658A (ja) 2002-02-05
US20010007758A1 (en) 2001-07-12

Similar Documents

Publication Publication Date Title
PT1818343E (pt) Anticorpos contra a il-12 humana
IL205765A0 (en) Mammalian cytokine: interleukin - b - 30 and isolated polunucleotides encoding the same
GB2337406B (en) Scheduling circuitry and methods
IL137761A0 (en) Treatment of multiple sclerosis using cop-1 and th-2 enhancing cytokines
EP1102535A4 (fr) Composes et procedes
GB9703547D0 (en) Telecommunications arrangements and methods
ZA962768B (en) Benzonitriles and benzofluorides
ZA986671B (en) Block copolymers and preparation thereof
IL139011A0 (en) Gene coding for helimicine and use thereof
GB9806666D0 (en) Antigen preparation and use
ZA965342B (en) Beta-xylosidase nucleotide sequence encoding it and use thereof
HUP0100668A3 (en) Virulence-associated nucleic sequences and uses thereof
GB9819898D0 (en) New vaccine and method of use
GB9808264D0 (en) Biochemical devices and their methods of manufacture
EP0999273A4 (fr) GENE HUMAIN RecQ4 CODANT HELICASE
GB9704349D0 (en) Levobupivacaine and its use
HUP9800146A3 (en) Thalidomide-derivatives and use of them
GB9704370D0 (en) Levobupivacaine and its use
ZA986247B (en) Antacid and papain combination
EP1063290A4 (fr) Nouvelle dicarbonylreductase et gene la codant
EP1092441A4 (fr) Joint de seringue chargee et seringue chargee
PL326573A1 (en) Novel paragene and method of obtaining same
GB9722023D0 (en) Levobupivacaine and its use
GB9826894D0 (en) Chemokine and uses thereof
GB9805087D0 (en) DNA sequences and their use